The efficacy and safety of SFI combined with chemotherapy have been obvious to all, but whether its combination with EGFR-TKIs can prolong the survival of NSCLC patients clinically and why the mechanism of delaying its drug resistance still need to be deeply explored. Here, EGFR is linked to non-small cell lung carcinoma.